3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Solid Tumors
1
Sarcoma
1
Pancreatic Neoplasms
1
Neuroendocrine Tumors
1
Neuroectodermal Tumors, Primitive
1
Liver Neoplasms
1
Kidney Neoplasms
1
Glioma
1
Glioblastoma
1
Esophageal Neoplasms
1
Castration Resistant Prostate Cancer
1
Carcinoma, Renal Cell
1
Carcinoma, Hepatocellular
1
Interventions
Triamcinolone Acetonide
1
TH 302
1
Specimen Handling
1
Magnetic Resonance Spectroscopy
1
Injections, Intramuscular
1
2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Castration Resistant Prostate Cancer
×
TH 302
×
Clear all
NCT06836726
2026-01-28
EVO
University Health Network, Toronto
Phase 2
Not yet recruiting
35 enrolled